CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases  by Cai, Miaotian et al.
Respiratory Medicine (2013) 107, 1444e1452Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedCCL18 in serum, BAL fluid and alveolar
macrophage culture supernatant
in interstitial lung diseasesMiaotian Cai a,b, Francesco Bonella a, Xuan He a,c,
Stephan U. Sixt d, Rafael Sarria e, Josune Guzman f,
Ulrich Costabel a,*aDepartment of Pneumology and Allergology, Ruhrlandklinik, University Hospital, University Duisburg-
Essen, Tueschener Weg 40, D-45239 Essen, Germany
bThe 3rd Department of Infectious Disease Center, Beijing You-An Hospital, Capital Medical University,
100069 Beijing, China
cBeijng Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University,
100020 Beijing, China
dDepartment of Anesthesiology, University Hospital Du¨sseldorf, 40225 Du¨sseldorf, Germany
eDepartment of Neurosciences, Faculty of Medicine and Dentistry, Basque Country University,
48940 Leioa, Spain
fGeneral and Experimental Pathology, Ruhr University, 44789 Bochum, GermanyReceived 6 February 2013; accepted 3 June 2013
Available online 5 July 2013KEYWORDS
CCL18;
Interstitial lung
disease;
Hypersensitivity
pneumonitis;
Idiopathic pulmonaryAbbreviation list: AaO2, alveolar-arte
CC chemokine; ATS/ERS, American T
kine ligand; COP, cryptogenic organiz
diffusing capacity of the lung for car
persensitivity pneumonitis; HRCT, hig
leukin; ILD, interstitial lung disease; IP
non-specific interstitial pneumonia; P
disease; SaO2, oxygen percent satura
* Corresponding author. Tel.: þ49 2
E-mail address: ulrich.costabel@ru
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Background: CCL18 is a CC chemokine produced mainly by antigen-presenting cells, and is
chemotactic predominantly for T-lymphocytes. CCL18 can stimulate pulmonary fibroblasts
and increase the collagen production in vitro.
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fluids between various interstitial lung diseases (ILDs), and to reveal potential correlations
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CCL18 in interstitial lung diseases 1445fibrosis;
Inflammation;
FibrosisMethods: Serum and bronchoalveolar lavage fluid (BALF) samples were collected from 199 pa-
tients with idiopathic pulmonary fibrosis (IPF), idiopathic non-specific interstitial pneumonia
(iNSIP), respiratory bronchiolitis interstitial lung disease/desquamative interstitial pneumonia
(RB-ILD/DIP), cryptogenic organizing pneumonia (COP), hypersensitivity pneumonitis (HP) or
sarcoidosis. Alveolar macrophage (AM) culture was performed in 44 patients with IPF, iNSIP,
COP, HP, sarcoidosis or non-ILDs. The CCL18 levels in serum, BALF and AM culture supernatant
were measured with ELISA.
Results: Both serum and BALF CCL18 levels in all ILDs were higher than in controls (all
p < 0.005). In HP, CCL18 serum levels were the highest of all ILDs, and its BALF levels were
significantly higher than in other ILDs except iNSIP. The BALF CCL18 levels markedly correlated
with BAL cell differentials, especially with the percentage of BAL lymphocytes. In AM culture
supernatant, the spontaneous CCL18 production was higher in HP and COP than in IPF and con-
trols.
Conclusion: CCL18 levels in serum, BALF and AM culture supernatant are markedly increased in
various inflammatory and fibrotic ILDs. However, the CCL18 level being highest in HP among
the investigated ILDs suggests that CCL18 may be more profoundly involved in inflammatory
immune responses.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
CC chemokine ligand 18 (CCL18), also called pulmonary and
activity-regulated chemokine (PARC) [1], monocyte in-
flammatory protein-4 (MIP-4) [2], dendritic cell-chemokine-
1 (DC-CK-1) [3], or alternative macrophage activation-
associated CC chemokine-1 (AMAC-1) [4], is a CC chemo-
kine which is produced primarily by antigen-presenting
cells [1,3,5e7], such as macrophages, dendritic cells, and
peripheral blood monocytes. Besides antigen-presenting
cells also mast cells, eosinophils and neutrophils are po-
tential producers of CCL18 under specific stimuli [8e10].
CCL18 is chemotactic for both naive and activated T-lym-
phocytes [1]. CCL18 is constitutively expressed in healthy
humans [4], while up-regulated CCL18 mRNA or protein
levels have been detected in serum, bronchoalveolar
lavage fluid (BALF) or sputum of patients with T-helper 2
(Th2)-predominant diseases such as idiopathic pulmonary
fibrosis (IPF) [11], bronchial asthma [12,13] and sclero-
derma [14]. CCL18 has been shown to play a role in various
fibrotic lung disorders [11,15]. CCL18 can stimulate the
mRNA and protein production of collagen in normal human
lung fibroblasts in vitro [15,16], and IPF patients with a
CCL18 serum level exceeding 150 ng/ml had a higher risk of
mortality [11].
IPF, idiopathic non-specific interstitial pneumonia
(iNSIP), respiratory bronchiolitis interstitial lung disease/
desquamative interstitial pneumonia (RB-ILD/DIP) and
cryptogenic organizing pneumonia (COP) are members of
idiopathic interstitial pneumonias (IIPs) [17]. IPF is a chronic
and fatal disease characterized by progressive fibrosis and
architectural destruction of the lung parenchyma. Hyper-
sensitivity pneumonitis (HP) is an inflammatory lung disor-
der characterized by diffuse lymphocytic interstitial
infiltration caused by repeated exposure to organic particles
in susceptible subjects [18,19]. Sarcoidosis is a multisystem
granulomatous disorder of unknown etiology most
commonly affecting lung tissues [20]. Both HP and pulmo-
nary sarcoidosis present as Th1-predominant lung disorders[20,21] characterized by local accumulation of activated T-
lymphocytes [20,22], albeit T-cell subpopulations are
different. In BALF, the predominant T-cell subset in HP is
CD8þ while that in sarcoidosis is CD4þ [23].
This study aimed to compare CCL18 levels in serum,
BALF and alveolar macrophage (AM) culture supernatant
between various ILDs characterized by fibrosis or inflam-
mation. Additionally, we explored potential correlations
between CCL18 levels and BAL cell differentials and clinical
parameters.Methods
Study population
Serum and BALF samples were collected from 199 consec-
utive patients with various ILDs including IPF (nZ 54), iNSIP
(n Z 30), RB-ILD/DIP (n Z 11), COP (n Z 26), HP (n Z 34)
and sarcoidosis (n Z 44, stage I: n Z 15, stage II: n Z 17,
stage III: n Z 8, stage IV: n Z 4). 61 serum and 10 BALF
samples from healthy volunteers served as controls. The
characteristics of these subjects are shown in Table 1. AM
culture supernatants were collected from another 44 sub-
jects including 9 IPF, 7 iNSIP, 6 COP, 9 HP, 7 sarcoidosis and
6 non-ILD controls with a normal BAL cytology (Table 2).
This study was approved by the institutional review board
(IRB 06-3170), and written informed consent was obtained
from the enrolled subjects.
Patients with IIPs were diagnosed according to the
American Thoracic Society/European Respiratory Society
(ATS/ERS) criteria [17] by clinical features, high-resolution
computed tomography (HRCT), laboratory and histological
findings. Each patient with IIP underwent a physical ex-
amination, pulmonary function tests, chest computed to-
mography (CT), and/or surgical lung biopsy. Patients with
interstitial pneumonia of known cause, such as drug, radi-
ation, collagen vascular diseases, or hypersensitivity
pneumonia were excluded. In IPF patients, eight had
Table 1 Demographics and laboratory characteristics of subjects for CCL18 measurements in serum and BALF.
IPF
(n Z 54)
iNSIP
(n Z 30)
RB-ILD/DIP
(n Z 11)
COP
(n Z 26)
HP
(n Z 34)
Sarc
(n Z 44)
Controls
(n Z 61)
Age (years) 69  1z 69  2z 53  4 57  3z 62  2z 48  2 48  1
Gender (male/female) 44/10 20/10 8/3 12/14 14/20 23/21 24/37
Smoking habit
Nonsmoker 24 17 0 16 22 26 44
Ex- & current smoker
(pack-year)
30 (24) 13 (26) 11 (32) 10 (25) 12 (34) 18 (21) 17
Steroid therapy (yes/no) 17/37 12/18 1/10 4/22 13/21 13/31 0/61
Lung biopsy 8 (15%) 6 (20%) 4 (36%) 13 (50%) 8 (24%) 29 (66%) 0
BAL cell differential
Total cell count (105/ml) 1  0.2 1  0.2y 4  2y 2  0.4y 3  0.4z 2  0.3y 1  0.1
Macrophages (%) 76  2y 68  4z 84  5 58  6y 36  3z 63  4z 87  3
Lymphocytes (%) 9  1 16  2 7  2 30  5y 53  4z 28  3z 12  3
Neutrophils (%) 12  2z 14  3z 8  3y 9  3y 9  1z 9  3 1  0.3
Eosinophils (%) 3  0.4z 3  1z 1  0.4 3  1y 3  1z 1  0.2 0.2  0.1
Mast cells (%) 0.3  0.1 0.5  0.1 0.2  0.1 1  0.2y 0.4  0.1 0.2  0.04 0.1  0.1
CD4þ lymphocytes (%) 10  2 15  3 21  5 35  4 23  3
CD8þ lymphocytes (%) 6  1 9  2 21  3 18  2 8  1
CD4/CD8 ratio 3  1 3  1 2  0.5 3  0.5 5  1
Pulmonary function
FEV1 (%pred) 71  3z 65  3z 66  6y 76  5y 67  3z 79  4y 106  5
VC (%pred) 68  3z 65  3z 81  5 84  5 70  3z 87  4 102  3
DLco (%pred) 42  2z 44  3z 53  4y 60  5z 37  3z 69  3z 125  18
Blood gas analysis
PaO2 (mmHg) 72  2 71  2z 71  3y 69  2z 66  1z 77  2y 92  1
AaO2 (mmHg) 30  2 28  2 31  3 36  2y 37  2y 23  2 24  1
SaO2 (%) 95  0.5 94  1 95  0.5 95  0.5 94  0.4y 96  0.3 97  0
Data are numbers or mean  SE.
Abbreviations: IPF Z idiopathic pulmonary fibrosis; iNSIP Z idiopathic non-specific interstitial pneumonia; RB-ILD Z respiratory
bronchiolitis interstitial lung disease; DIP Z desquamative interstitial pneumonia; COP Z cryptogenic organizing pneumonia;
HP Z hypersensitivity pneumonitis; Sarc Z sarcoidosis; BAL Z bronchoalveolar lavage; FEV1 Z forced expiratory volume in 1 s;
VC Z vital capacity; DLco Z diffusing capacity of the lung for carbon monoxide; PaO2 Z arterial oxygen tension; AaO2 Z alveolar-
arterial PaO2 difference; SaO2 Z arterial oxygen saturation.
yp < 0.05, zp < 0.005 (vs. controls).
1446 M. Cai et al.undergone lung biopsy; in NSIP six patients. All patients
with NSIP had the idiopathic form, no one had connective
tissue diseases.
Patients with HP fulfilled the following diagnostic
criteria [1]: a history of exposure to organic antigens [2],
clinical signs and symptoms consistent with HP [3], radio-
logic features and/or functional abnormalities character-
istic of ILD [4], evidence of serum precipitins against one or
more organic antigens [5], BALF with increased lympho-
cytes. There were 12 acute/subacute HP and 22 chronic HP.
The definition of these clinical forms of HP has been
described previously [24]. Patients with sarcoidosis were
diagnosed based on compatible clinical and radiological
features, histological evidence of noncaseating granuloma
in tissue biopsy or an increased CD4/CD8 ratio in BALF, and
the exclusion of other granulomatous lung diseases.
BAL procedure
BAL was performed via a fiberoptic bronchoscope. Briefly, a
total volume of 100e120 ml of sterile isotonic saline was
instilled into the right middle or left lingular lobe withimmediate aspiration after each aliquot. The recovery rate
was about 50%. The recovered BALF was filtered through 2-
layer sterile gauze and centrifuged at 500g for 10 min at
4 C. The supernatant was collected and stored at 80 C.
Cell pellets were resuspended in PBS for differential cell
counts and cell culture. Serum samples were obtained at
the day of bronchoscopy and stored at 80 C until further
procedures.
Isolation and culture of alveolar macrophages (AMs)
BAL cell pellets were washed three times with PBS, and
suspended with RPMI-1640 (Invitrogen, Karlsruhe, Ger-
many) containing 10% heat-inactivated fetal bovine serum
(Biochrom AG, Berlin, Germany), 2 mM L-glutamine, 200 U/
ml penicillin and 200 mg/ml streptomycin (Invitrogen). The
cell suspension was added at 0.5  106 cells/well to a 24-
well plastic tissue culture plate (Falkon, Becton Dick-
inson, New Jersey, USA) and incubated at 37 C in a 5% CO2
humidified milieu for 1 h to permit the adherence of AMs.
Then the non-adherent cells were removed by three washes
with 2% RPMI-1640. The purity of adherent AMs was
Table 2 Demographics and laboratory characteristics of subjects for CCL18 measurements in cell culture supernatants.
IPF
(n Z 9)
iNSIP
(n Z 7)
COP
(n Z 6)
HP
(n Z 9)
Sarc
(n Z 7)
Controlsa
(n Z 6)
Age (years) 71  3z 61  5 62  4 58  5 46  7 47  6
Gender (male/female) 8/1 3/4 5/1 2/7 2/5 3/3
Current smoker (yes/no) 3/6 0/7 0/6 0/9 0/7 4/2
Steroid treatment (yes/no) 0/9 0/7 0/6 0/9 0/7 0/6
Lung biopsy 2 (22%) 0 4 (67%) 2 (22%) 4 (57%) 2 (33%)
BAL cell differential
Total cell count (105/ml) 3  0.3 4  1 4  0.5 4  0.5 3  0.2 5  1
Macrophages (%) 82  4z 63  8z 44  15y 25  8z 46  12z 97  2
Lymphocytes (%) 6  1 18  6y 25  9y 69  8z 52  12z 4  2
Neutrophils (%) 10  3y 17  6z 27  11y 4  1 1  1 1  0.4
Eosinophils (%) 2  1 2  1 4  2y 1  0.3y 0.5  0.1y 0.1  0.1
Mast cells (%) 0.3  0.5 0.3  0.1 1  1 1  2y 0.3  0.5 0  0
Pulmonary function
FEV1 (%pred) 82  9 61  9y 53  6z 66  7y 86  3 98  6
VC (%pred) 83  8 64  9y 60  10y 69  7y 100  3 104  6
DLco (%pred) 46  6y 53  4 41  3y 45  4z 71  6 76  8
Blood gas analysis
PaO2 (mmHg) 71  3 78  5 63  8 71  4 76  5 75  4
AaO2 (mmHg) 32  3 24  7 37  5 31  5 23  4 26  4
SaO2 (%) 95  1 96  1 93  1y 95  1 96  1 96  1
Data are numbers or mean  SE.
Abbreviations: IPF Z idiopathic pulmonary fibrosis; iNSIP Z idiopathic non-specific interstitial pneumonia; COP Z cryptogenic orga-
nizing pneumonia; HP Z hypersensitivity pneumonitis; Sarc Z sarcoidosis; BAL Z bronchoalveolar lavage; FEV1 Z forced expiratory
volume in 1 s; VC Z vital capacity; DLco Z diffusing capacity of the lung for carbon monoxide; PaO2 Z arterial oxygen tension;
AaO2 Z alveolar-arterial PaO2 difference; SaO2 Z arterial oxygen saturation.
yp < 0.05, zp < 0.005 (vs. controls).
a Controls are non-ILD patients with a normal BAL cytology.
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specific esterase staining. Then fresh 10% RPMI with or
without 100 ng/ml LPS (SigmaeAldrich, St. Louis, MO) was
added to relative wells and incubated for another 24 h.
Eventually, cell-free supernatants were harvested and
stored at 80 C for ELISA.
Enzyme-linked immunosorbent assay (ELISA)
CCL18 levels in serum, BALF and AM culture supernatant were
quantified using human CCL18 duoset ELISA development
systems (R&D Systems Europe, Abingdon, UK) with a detect-
able range from 7.8 to 500 pg/ml. The ELISA was performed
according to the manufacturer’s instructions. The CCL18
level in AM culture supernatant was expressed as ng/ml/
106AMs after correction for the proportion of AMs in BALF.
Statistical analysis
Demographic data are expressed as numbers or mean  SE.
CCL18 levels are expressed as median and interquartile
range (IQR). The KruskaleWallis one-way analysis of vari-
ance on ranks was performed for comparison of all groups.
The difference between groups was compared using the
ManneWhitney U-test. The correlation between CCL18
levels and clinical or laboratory parameters was analyzed
by the Spearman rank test and verified by regression
analysis. A p < 0.05 was considered statistically significant.Results
CCL18 was detectable in all serum, BALF and AM culture
supernatant samples from controls and patients.
CCL18 serum levels
As shown in Fig. 1A, in controls, the CCL18 serum level was
39 ng/ml (IQR: 44 ng/ml). All ILD groups had significantly
higher CCL18 serum levels than controls (all p < 0.001).
Within the ILD groups, HP had the highest level (median:
190 ng/ml, IQR: 302 ng/ml) which was significantly greater
than in IPF (median: 149 ng/ml, IQR: 179 ng/ml; p < 0.05),
iNSIP (median: 142 ng/ml, IQR: 136 ng/ml; p < 0.05), COP
(median: 146 ng/ml, IQR: 118 ng/ml; p< 0.05) or sarcoidosis
(median: 108 ng/ml, IQR: 67 ng/ml; p < 0.001). In IPF, the
serum CCL18 level was similar to that in iNSIP and COP (all
p > 0.05), but was higher than in sarcoidosis (p < 0.05). The
CCL18 serum level in RB-ILD/DIP (median: 161 ng/ml, IQR:
90 ng/ml) tended to be lower than in all other ILDs (vs. HP:
p Z 0.059; vs. other ILDs: p > 0.2). In acute/subacute HP,
the CCL18 serum level (median: 329 ng/ml, IQR: 348 ng/ml)
tended to be higher than in chronic HP (median: 170 ng/ml,
IQR: 227 ng/ml) (p > 0.05). In sarcoidosis, there was no
difference in the CCL18 serum level between the different
stages [stage I: 103 ng/ml (IQR: 79 ng/ml), stage II: 107 ng/ml
(IQR: 77 ng/ml), stage III: 95 ng/ml (IQR: 44 ng/ml), stage IV:
119 ng/ml (IQR: 64 ng/ml)] (all p > 0.05) (Fig. 2A).
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Figure 1 CCL18 levels in serum (A) and BALF (B) in various
interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis
(IPF) n Z 54, idiopathic non-specific interstitial pneumonia
(iNSIP) n Z 30, respiratory bronchiolitis interstitial lung dis-
ease/desquamative interstitial pneumonia (R/D) n Z 11,
cryptogenic organizing pneumonia (COP) n Z 26, hypersensi-
tivity pneumonitis (HP) n Z 34, sarcoidosis (Sarc) n Z 44,
controls nZ 61 (for BALF, nZ 10). The central line represents
the median, the boxes represent the interquartile range and
the whiskers represent min & max values.
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Figure 2 CCL18 levels in serum (A) and BALF (B) in different
stages of sarcoidosis. Stage I n Z 15, Stage II n Z 17, Stage III
nZ 8, Stage IV nZ 4. The central line represents the median,
the boxes represent the interquartile range and the whiskers
represent min & max values.
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The CCL18 BALF level in healthy controls was 1 ng/ml (IQR:
2 ng/ml). CCL18 BALF levels in all diseases were higher than
in controls (all p < 0.005). The CCL18 BALF level in HP
(median: 13 ng/ml, IQR: 10 ng/ml) was significantly higher
than in IPF (median: 6 ng/ml, IQR: 5 ng/ml; p < 0.001), RB-
ILD/DIP (median: 4 ng/ml, IQR: 4 ng/ml; p < 0.001), COP
(median: 5 ng/ml, IQR: 8 ng/ml; p < 0.05) or sarcoidosis
(median: 7 ng/ml, IQR: 9 ng/ml; p < 0.001), but was similar
to iNSIP (median: 9 ng/ml, IQR: 12 ng/ml; p > 0.05)
(Fig. 1B). CCL18 BALF levels in acute/subacute HP (median:
15 ng/ml, IQR: 11 ng/ml) tended to be higher than in
chronic HP (median: 12 ng/ml, IQR: 8 ng/ml; p > 0.05). In
sarcoidosis, there was no difference in the CCL18 BALF
level between the different stages [stage I: 12 ng/ml (IQR:
16 ng/ml), stage II: 6 ng/ml (IQR: 7 ng/ml), stage III: 6 ng/
ml (IQR: 9 ng/ml), stage IV: 7 ng/ml (IQR: 5 ng/ml)] (allp > 0.05) (Fig. 2B), though there was a tendency for
decreasing CCL18 BALF levels with increasing radiologic
stages.
Correlations between CCL18 levels and clinical/
laboratory parameters
In the pool of patients, the CCL18 serum level correlated
with the CCL18 BALF level (Fig. 3A). The CCL18 BALF level
correlated with the BAL cell count (Fig. 3B) and the per-
centage of lymphocytes (Fig. 3C), as well as the counts of
lymphocytes (r Z 0.39, p < 0.001). The BALF CCL18 level
also correlated with the percentage and count of BAL CD4þ
T-lymphocytes (r Z 0.31, p < 0.005 and r Z 0.30,
p < 0.005, respectively).
Correlations between CCL18 levels and clinical/
laboratory parameters in individual ILDs
IPF: The CCL18 BALF level in IPF correlated with the counts
of BAL total cells (r Z 0.50, p < 0.001), macrophages
(rZ 0.54, p < 0.001) and eosinophils (rZ 0.31, p < 0.05).
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Figure 3 Correlation between CCL18 serum level and (A) CCL18 BALF level. Correlation between CCL18 BALF level and (B) BAL
cell count, and (C) lymphocytes in ILD patients.
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Figure 4 Spontaneous and LPS-stimulated production of
CCL18 in AM culture supernatant. Idiopathic pulmonary fibrosis
(IPF) n Z 9, idiopathic non-specific interstitial pneumonia
(iNSIP) nZ 7, cryptogenic organizing pneumonia (COP) nZ 6,
hypersensitivity pneumonitis (HP) n Z 9, sarcoidosis (Sarc)
nZ 7, controls nZ 6. The central line represents the median,
the boxes represent the interquartile range and the whiskers
represent min & max values.
CCL18 in interstitial lung diseases 1449iNSIP: The CCL18 BALF level in iNSIP correlated with the
counts of BAL total cells (r Z 0.39, p < 0.05) and macro-
phages (r Z 0.45, p < 0.05).
RB-ILD/DIP: The CCL18 BALF level in RB-ILD/DIP corre-
lated with the counts of BAL total cells (rZ 0.78, p < 0.01),
macrophages (rZ 0.80, p < 0.005), lymphocytes (rZ 0.67,
p < 0.05), neutrophils (r Z 0.64, p < 0.05) and eosinophils
(r Z 0.70, p < 0.05), and inversely with FVC (%pred,
rZ 0.61, p < 0.05). Both the CCL18 serum and BALF levels
in this group were inversely associated with DLco (%pred,
rZ 0.73, p < 0.05 and rZ 0.67, p < 0.05, respectively).
COP: The CCL18 BALF level in COP correlated inversely
with DLco (%pred, r Z 0.67, p < 0.01). The CCL18 serum
level correlated inversely with FEV1 (rZ 0.67, p < 0.005)
and VC (r Z 0.66, p < 0.005).
HP: The CCL18 BALF level in HP correlated with the
count of BAL mast cells (r Z 0.42, p < 0.05).
Sarcoidosis: The CCL18 BALF level in sarcoidosis corre-
lated with the percentage of BAL lymphocytes (r Z 0.37,
p < 0.05). The CCL18 serum level correlated inversely with
DLco (%pred, r Z 0.48, p < 0.005).
CCL18 in AM culture supernatants
As shown in Fig. 4, in AM culture supernatant, the sponta-
neous production of CCL18 was significantly increased in HP
and COP compared to IPF (p < 0.01) and controls
(p < 0.005). LPS failed to affect the CCL18 production by
AMs both in ILDs and controls (p > 0.05). In the pool of ILD
patients (n Z 38), the spontaneous CCL18 productioncorrelated with the percentage of BAL lymphocytes
(r Z 0.35, p < 0.05) and inversely with the percentage
(r Z 0.66, p < 0.001) and the count of BAL macrophages
(r Z 0.45, p < 0.01).
1450 M. Cai et al.Discussion
This study showed that CCL18 serum and BALF levels are
markedly increased in various ILDs suggesting that CCL18 is
involved in the pathogenesis of these disorders. Among the
investigated ILDs, HP showed the highest CCL18 levels both
in serum and BALF. HP is caused by repeated inhalation of
organic particles, thus antigen presentation and hypersen-
sitivity reactions are profoundly involved in the develop-
ment of this entity. Antigen-presenting cells are primary
sources of CCL18 [1,3,5e7]. Thus, we suppose that acti-
vated antigen-presenting cells, especially AMs in the lung in
HP, are responsible for the amplified CCL18 levels in HP.
Inline with this hypothesis we found pronounced in vitro
production of CCL18 by AMs in HP. Moreover, the correlation
between the CCL18 BALF level and the percentage of BAL
lymphocytes in this study may support the idea that CCL18
contributes to the lymphocytic accumulation in local in-
flammatory sites. In our HP patients, the BAL and serum
levels of CCL18 in acute/subacute HP tended to be higher
than in chronic HP. This is in agreement with a previous
observation that HP patients with the highest levels of
CCL18 expression in lung tissue had subacute rather than
chronic HP [25].
In contrast to Th1-cytokine-driven HP, IPF is a Th2-
predominant disease [26]. A recent study showed that the
percentage of CCL18-positive AMs are increased in several
fibrotic lung diseases including IPF, iNSIP and scleroderma
lung [27]. However, in our study, AMs in IPF released similar
levels of CCL18 as controls, suggesting that cells other than
AMs contribute to the augmented CCL18 in BALF in IPF. Such
cells may be reactive type 2 pneumocytes [25]. Moreover,
the correlation between the CCL18 BALF level and the cell
count of BAL eosinophils in our IPF patients provided an
evidence of a link between these inflammatory cells and
the CCL18 production in BALF. Inline with that, elevated
expressions of CCL18 mRNA in BAL cells and the CCL18
protein in BALF have been found in scleroderma patients
with lung inflammation characterized by eosinophilia and
neutrophilia [14]. So far, the CCL18 serum level, but not the
CCL18 BALF level, has been documented as an indicator of
the activity of fibrosis and/or prognosis in pulmonary
fibrotic diseases, such as IPF and systemic sclerosis-
associated ILD [11,27e29].
Although CCL18 can stimulate the mRNA and protein
production of collagen in normal human lung fibroblasts
in vitro [15,16], CCL18 may mediate the fibrogenesis in vivo
through a different, T-lymphocyte-dependent pathway. In a
CCL18-gene-transfer mouse model, CCL18 selectively pro-
moted long-term pulmonary T-lymphocyte infiltration and
infiltration-dependent collagen accumulation [30]. More-
over, the CCL18-mediated T-lymphocyte infiltration can
even be partially antifibrotic, since overexpression of
CCL18 in the bleomycin-induced lung injury model
enhanced T-cell infiltration and cytokine expression
including TNF-a and IFN-g but attenuated bleomycin-
induced collagen accumulation [31], suggesting that the
regulation of CCL18-mediated inflammation and fibrosis is
complex and occurs through mechanisms that involve T-
lymphocytic infiltration. Inline with this, high CCL18 levels
have been observed in lung tissues in an ILD characterizedby T-lymphocyte accumulation such as HP in comparison
with IPF, and CCL18 was preferentially expressed in areas
with more inflammation and less fibrosis of lung tissues in
HP [25]. The same study also showed a close correlation
between the CCL18 tissue level and the percentage of BAL
lymphocytes, much inline with what we have found and in
contrast to others who did not find a correlation between
BAL cell-derived CCL18 and BAL lymphocytes [15].
Moreover, we detected high CCL18 levels in serum and
BALF in sarcoidosis. There are discrepant data on CCL18 in
sarcoidosis in the literature. One study showed that the
CCL18 mRNA expression in BAL cells in sarcoidosis was
similar to that in controls and did not correlate with the
number of BAL lymphocytes [32]. Another study showed, in
agreement with our data, that BAL-derived cells from
sarcoid patients produced significantly more CCL18 than
healthy controls [15]. Recently, increased gene expression
of CCL18 in AMs and a positive correlation between CCL18
expression and the percentage of BAL lymphocytes has
been reported in sarcoidosis [33]. Differences in methods
(mRNA versus protein analysis) and in the characteristics of
included patients may account for the different results.
It is well known that CCL18 attracts predominantly
lymphocytes. One study investigating CCL18 injected into
the peritoneal cavity of mice suggested that the chemo-
tactic effects of CCL18 on CD4þ and CD8þ cells are equal
[34]. In contrast, we observed a closer relation in ILD pa-
tients between the CCL18 BALF level and CD4þ lympho-
cytes than with the CD8þ subtype. This relation was
highlighted in the HP and sarcoidosis groups, possibly indi-
cating a preferential chemotactic effect of CCL18 on CD4þ
cells in these diseases.
In this study, LPS failed to stimulate the AM production
of CCL18. So far, the effect of LPS on CCL18 production is
controversial. It was noticed that LPS can augment CCL18
protein and mRNA levels in blood monocytes and in
monocyte-derived macrophages [8,35,36], whereas LPS
downregulates CCL18 levels in dendritic cells [37]. The
paradox between different studies suggests different
modulating effects of LPS in different experimental condi-
tions and clinical situations.
We found no correlation between smoking habits of ILD
patients or healthy controls and their serum or BALF CCL18
levels. However, patients with smoking-related RB-ILD/DIP
[38] showed the lowest CCL18 levels in all ILDs in their
serum and BALF which were close to controls, indicating
that CCL18 levels in biological fluids may be rather low in
smoking-related diseases. Interestingly, although similar
CCL18 levels have been detected in serum and BALF of
healthy smokers and nonsmokers, BAL cells (mainly AMs)
from smokers released less CCL18 protein than those from
nonsmokers, suggesting that smoking may alter the activity
of AMs and potentially abrogate their CCL18 production
[39]. Partially in contrast, we observed similar levels of AM-
released CCL18 in smokers and nonsmokers in ILD patients
(data not shown).
Several limitations of this study need to be discussed.
Firstly, the number of patients in each disease group was
rather small which contributed to enlarge the variance of
the mean of CCL18 levels and reduced the power of sta-
tistical analysis. This may affect the interpretation of the
results. Secondly, the isolation method for AMs in this study
CCL18 in interstitial lung diseases 1451did not allow to separate dendritic cells from AMs. How-
ever, studies have shown that the proportion of dendritic
cells is very low in BALF both in healthy volunteers and in
ILD patients [40,41]. Thus, we supposed that the contri-
bution of dendritic cells to the CCL18 production in the
culture supernatant is negligible. Thirdly, longitudinal in-
vestigations regarding the relationship between the CCL18
expression and the pulmonary function impairment or the
prognosis have not been performed. Fourthly, factors
influencing the CCL18 expression in ILDs have not been
studied. Moreover, the mechanisms how CCL18 affects in-
flammatory and fibrotic responses in ILDs have not been
investigated.
In conclusion, CCL18 levels are augmented in various
biological fluids in inflammatory and fibrotic ILDs. The
CCL18 level being highest in HP among the investigated ILDs
suggests that CCL18 is more profoundly involved in inflam-
matory responses.
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